ACL.AX ASX
Australian Clinical Labs Limited
1W: +0.7%
1M: +3.0%
3M: +22.4%
YTD: +11.2%
1Y: +6.9%
3Y: +3.7%
5Y: -21.2%
A$2.81 ($1.95)
+0.02 (+0.72%)
Weekly Expected Move ±3.4%
A$3
A$3
A$3
A$3
A$3
Overview
Chart
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ETF Exposure
Income Trends
Revenue
$730M
-1.6% ▼
5Y CAGR: +2.6%
Gross Profit
$150M
-44.5% ▼
5Y CAGR: -22.0%
Operating Income
$61M
-77.3% ▼
5Y CAGR: -12.9%
Net Income
$24M
-26.9% ▼
5Y CAGR: -17.0%
EPS (Diluted)
$0.12
-29.4% ▼
5Y CAGR: -21.4%
EBITDA
$197M
+141.9% ▲
5Y CAGR: +0.0%
Profit Margins
Year-over-Year Growth
View Full Income Statement
| Line Item | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
| Revenue | $989M | $692M | $690M | $741M | $730M |
| YoY Growth | +54.3% | -30.0% | -0.3% | +7.5% | -1.6% |
| Cost of Revenue | $208M | $126M | $551M | $470M | $579M |
| Gross Profit | $782M | $566M | $138M | $271M | $150M |
| Gross Margin | 79.0% | 81.8% | 20.1% | 36.5% | 20.6% |
| R&D Expenses | $0 | $0 | $0 | $0 | $0 |
| SG&A Expenses | $314M | $297M | $87M | $0 | $89M |
| Operating Expenses | $514M | $514M | $82M | $90M | $89M |
| Operating Income | $268M | $56M | $57M | $271M | $61M |
| Operating Margin | 27.1% | 8.1% | 8.3% | 36.5% | 8.4% |
| Interest Expense | $12M | $14M | $17M | $18M | $18M |
| Income Before Tax | $255M | $48M | $36M | $48M | $37M |
| Tax Expense | $76M | $12M | $12M | $15M | $13M |
| Net Income | $178M | $36M | $24M | $32M | $24M |
| Net Margin | 18.0% | 5.2% | 3.5% | 4.4% | 3.3% |
| EPS (Diluted) | $0.88 | $0.18 | $0.12 | $0.17 | $0.12 |
| EBITDA | $373M | $185M | $170M | $81M | $197M |
| Shares Outstanding | 201M | 201M | 199M | 190M | 192M |